Advertisement

ADVERTISEMENT

Follicular Lymphoma

Dr M
Videos
Dr McKinney on the Efficacy, Safety of Parsaclisib for R/R FL
02/15/2022
Matthew McKinney, MD, overviews the phase 2 CITADEL-203 study on parsaclisib in patients with R/R FL, presented at ASH 2021.
Matthew McKinney, MD, overviews the phase 2 CITADEL-203 study on parsaclisib in patients with R/R FL, presented at ASH 2021.
Matthew McKinney, MD, overviews...
02/15/2022
Oncology
idea
Test Your Knowledge
Quiz: Tisagenlecleucel Therapy in Patients With High-Risk R/R FL
01/06/2022
True or false: Tisagenlecleucel induces high response rates in adult patients with high-risk R/R FL.
True or false: Tisagenlecleucel induces high response rates in adult patients with high-risk R/R FL.
True or false: Tisagenlecleucel...
01/06/2022
Oncology
News
Tisagenlecleucel Therapy Produces High Response Rates in Patients With High-Risk R/R FL
01/06/2022
Efficacy data of tisagenlecleucel in adult patients with high-risk R/R FL were presented at the 2021 ASH Annual Meeting to update results from the overall population at a median follow-up of 17 months and report a subgroup analysis of...
Efficacy data of tisagenlecleucel in adult patients with high-risk R/R FL were presented at the 2021 ASH Annual Meeting to update results from the overall population at a median follow-up of 17 months and report a subgroup analysis of...
Efficacy data of...
01/06/2022
Oncology
Test Your Knowledge
Quiz: Remission Duration in R/R FL After Multiple Lines of Therapy
07/29/2021
True or False: Remissions are shorter among patients with R/R FL after multiple prior lines of therapy.
True or False: Remissions are shorter among patients with R/R FL after multiple prior lines of therapy.
True or False: Remissions are...
07/29/2021
Oncology
News
Remissions Shorter for Patients With R/R FL After Multiple Therapy Lines
07/29/2021
It is uncommon for patients with R/R FL to achieve a CR after ≥2 prior lines of therapy, according to a meta-analysis presented at the virtual 2021 ASCO Annual Meeting.
It is uncommon for patients with R/R FL to achieve a CR after ≥2 prior lines of therapy, according to a meta-analysis presented at the virtual 2021 ASCO Annual Meeting.
It is uncommon for patients with...
07/29/2021
Oncology
Test Your Knowledge
Quiz: Which Combo Therapy Showed Superior Efficacy Over Monotherapy in Patients With FL, MZL?
06/15/2021
Combining rituximab with which of the following therapies demonstrated superior efficacy when compared to rituximab alone in patients with relapsed FL/MZL?
Combining rituximab with which of the following therapies demonstrated superior efficacy when compared to rituximab alone in patients with relapsed FL/MZL?
Combining rituximab with which...
06/15/2021
Oncology
Conference Insider
Copanlisib Plus Rituximab Shows Superior Efficacy Over Monotherapy in FL, MZL
06/15/2021
Copanlisib when given in combination with rituximab demonstrated superior efficacy over rituximab monotherapy in patients with relapsed FL/MZL, according to study findings presented at the virtual 2021 ASCO Annual Meeting.
Copanlisib when given in combination with rituximab demonstrated superior efficacy over rituximab monotherapy in patients with relapsed FL/MZL, according to study findings presented at the virtual 2021 ASCO Annual Meeting.
Copanlisib when given in...
06/15/2021
Oncology
Test Your Knowledge
Quiz: Which Triplet Therapy Regimen Showed Promise in Patients With R/R FL?
06/14/2021
Combining polatuzumab vedotin and obinutuzumab with which of the following therapies led to improved response rates at the end of induction period in patients with relapsed/refractory FL?
Combining polatuzumab vedotin and obinutuzumab with which of the following therapies led to improved response rates at the end of induction period in patients with relapsed/refractory FL?
Combining polatuzumab vedotin...
06/14/2021
Oncology
Conference Insider
Triplet Therapy Shows Promise in Patients With R/R FL
06/03/2021
Treatment with polatuzumab vedotin, obinutuzumab, and venecolax, shows promise in the response rates at end of induction in patients with RR FL.
Treatment with polatuzumab vedotin, obinutuzumab, and venecolax, shows promise in the response rates at end of induction in patients with RR FL.
Treatment with polatuzumab...
06/03/2021
Oncology
Dr Evans Discusses Updates in the Treatment of Patients With FL
Videos
Dr Evans Discusses Updates in the Treatment of Patients With FL
01/29/2021
In this video, Andrew Evens, DO, MSc, FACP, discusses a couple of key publications and data sets in the field of EZH2-mutated and EZH2 wild type FL.
In this video, Andrew Evens, DO, MSc, FACP, discusses a couple of key publications and data sets in the field of EZH2-mutated and EZH2 wild type FL.
In this video, Andrew Evens, DO,...
01/29/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

September 18 ⁠–⁠ September 20
September 20 ⁠–⁠ September 22
September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use